[1] 胡利娟,周旻,尹一子,等. 复发苦参组注射液联合化疗治疗淋巴瘤临床疗效与安全性的Meta分析[J]. 现代医院,2015,15(12):21-24. [2] 陈灏珠.实用内科学[M]. 12版. 北京: 人民卫生出版社,2005: 2046-2410. [3] 涂峰,李贵良,苏星烽.孟鲁司特对哮喘患者外周血Th1/Th2平衡以及外周血炎症因子水平的影响[J]. 广州医药,2016,47(1):78-80. [4] 钟道清,罗育武,罗权.寻常性银屑病患者外周血Th1和Th17细胞亚群的研究[J]. 广州医药,2012,43(3):16-18. [5] 张晓君,王正昕,傅志仁. Th17 型细胞在移植排斥反应中的研究进展[J]. 中华器官移植杂志,2010,31(3):187-189. [6] NUMASAKI M, WATANABE M, SUZUKI T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis[J]. J Immunol,2005,175:6177-6189. [7] MIYAHARA Y, ODUNSI K, CHEN W, et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer[J]. Proc Natl Acad Sci USA,2008,105(40):15505-15510. [8] MURANSKI P, BONI A, ANTONY PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood,2008,112(2): 362-373. [9] MURANSKI P, NICHOLAS P. Does IL-17 promote tumor grooth[J]. Blood,2009,114(2):357-359. [10] KRYCZEK I, BANERJEE M, CHENG P, et al. Phenotype, distribution, generation,and functional and clinical relevance of Th17 cells in the human tumorenvironments[J]. Blood,2009,114(6):1141-1149. [11] CANTINI G, PISATI F, MASTROPIETRO A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment[J]. Cancer Immunol Immunother,2011,60(12):1739-1750. |